You are here:
Praluent
Extension of indication to include treatment of paediatric patients 8 years of age and older with heterozygous familial hypercholesterolemia (HeFH) as an adjunct to diet, alone or in combination with other LDL -C lowering therapies.
No estimate possible yet
Registration application pending
Alirocumab
Cardiovascular diseases
Indication extension
Lipid-lowering medications
Sanofi
Enzyme inhibitor
Subcutaneous
Injection
Extramural (GVS)
PCSK9 remmer
Centralised (EMA)
Normal trajectory
No
March 2023
January 2024
There is currently nothing known about the expected patient volume.
Voor alirocumab is een financieel arrangement van toepassing tot 1 januari 2027. Gemiddelde prijs per 1 wegwerpspuit Praluent, 1 ml injectievloeistof 150 mg/ml € 225,66 incl. btw.
There is currently nothing known about the possible total cost.
There is currently nothing known about off label use.
There is currently nothing known about indication extensions.
There is currently no futher information available.
Understanding of expected market entry of innovative medicines